Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: Systematic review of systematic reviews

BMJ Open

Volumn 7, Issue 3, 2017, Pages

  Collins, Dylan R J ^a   Tompson, Alice C ^a   Onakpoya, Igho J ^a   Roberts, Nia ^b   Ward, Alison M ^a   Heneghan, Carl J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cardiovascular risk assessment; primary prevention; risk score; total cardiovascular risk

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FOLLOW UP; HUMAN; META ANALYSIS; MORBIDITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; GLOBAL HEALTH; INTERNATIONAL COOPERATION; LITERATURE; PROCEDURES; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

CARDIOVASCULAR DISEASES; GLOBAL HEALTH; HUMANS; INTERNATIONALITY; PRIMARY PREVENTION; REVIEW LITERATURE AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 85016271981     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-013650     Document Type: Review

References (48)

1. World Health Organization. Cardiovascular diseases (CVDs). 2015. http://www.who.int/mediacentre/factsheets/fs317/en/ (accessed 4 Aug 2015)
2. WHO. Noncommunicable diseases, fact sheet. 2015. http://www. who.int/mediacentre/factsheets/fs355/en/
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
4. Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015;132:1667-78
5. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91
6. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2015. https://www.nice.org.uk/guidance/cg181/resources/guidancelipid-modification-cardiovascular-risk-assessment-and-themodification-of-blood-lipids-for-the-primary-and-secondaryprevention-of-cardiovascular-disease-pdf
7. WHO. Package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Geneva, Switzerland. 2010. http://apps.who.int/iris/handle/10665/ 44260 (accessed 27 Oct 2014)
8. NICE. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovasculardisease: methods, evidence, and recommendations. Published online first. 2014. http://www.nice.org.uk/guidance/cg181/evidence/ lipid-modification-update-full-guideline-243786637
9. Tang L, Patao C, Chuang J, et al. Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010). Am J Cardiol 2013;112:1126-32
10. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-23
11. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
12. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
13. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206
14. Camisasca P, Avanzini F, Alli C, et al. Overall cardiovascular risk still ignored in general practice care of hypertension. J Cardiovasc Risk 2002;9:147-52
15. Liew SM, Blacklock C, Hislop J, et al. Cardiovascular risk scores: qualitative study of how primary care practitioners understand and use them. Br J Gen Pract 2013;63:e401-7
16. Williams CL, Bollella M, Wynder E. Preventive cardiology in primary care. Atherosclerosis 1994;108(Suppl):S117-26
17. Goldman RE, Parker DR, Eaton CB, et al. Patients perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006;4:205-12
18. van Steenkiste B, van der Weijden T, Timmermans D, et al. Patients ideas, fears and expectations of their coronary risk: barriers for primary prevention. Patient Educ Couns 2004;55:301-7
19. Conroy RM, PyOrl K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
20. DAgostino RBS, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7
21. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136
22. Thomsen TF, McGee D, Davidsen M, et al. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002;31:817-22
23. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrance Collaboration, 2011, www.cochrane-handbook.org
24. Collins D, Tompson A, Roberts N, et al. Global cardiovascular risk assessment in the primary prevention of cardiovascular diseases in adults: an overview of systematic reviews. PROSPERO Int. Prospect. Regist. Syst. Rev. 2015. http://www.crd.york.ac.uk/PROSPERO/ display-record.asp?ID=CRD42015019821 (accessed 4 Aug 2015)
25. Emberson JR, Whincup PH, Morris RW, et al. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J 2003;24:1719-26
26. Cooper A, Nherera L, Calvert N, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners 2008;1-241
27. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10
28. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014
29. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6
30. GRADEpro GDT. GRADEpro Guideline Development Tool. 2015. http://www.gradepro.org
31. Brindle P, Beswick A, Fahey T, et al. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006;92:1752-9
32. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res 2008;8:60
33. Sheridan SL, Viera AJ, Krantz MJ, et al. The effect of giving global coronary risk information to adults. Arch Intern Med 2010;170:230-9
34. Waldron C-A, van der Weijden T, Ludt S, et al. What are effective strategies to communicate cardiovascular risk information to patients? A systematic review. Patient Educ Couns 2011;82: 169-81
35. van Dieren S, Beulens JWJ, Kengne AP, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360-9
36. Usher-Smith JA, Silarova B, Schuit E, et al. Impact of provision of cardiovascular disease risk estimates to healthcare professionals and patients: a systematic review. BMJ Open 2015;5:e008717
37. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK study. Imperial Cancer Research Fund OXCHECK Study Group. BMJ 1995;310:1099-104
38. Emmett CL, Montgomery AA, Peters TJ, et al. Three-year follow-up of a factorial randomised controlled trial of two decision aids for newly diagnosed hypertensive patients. Br J Gen Pract 2005;55:551-3
39. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. Family Heart Study Group. BMJ 1994;308:313-20
40. Persell SD, Lloyd-Jones DM, Friesema EM, et al. Electronic health record-based patient identification and individualized mailed outreach for primary cardiovascular disease prevention: a cluster randomized trial. J Gen Intern Med 2013;28:554-60
41. WHO. Prevention of cardiovascular disease: guidelines for the assessment and managment of cardiovascular risk. 2007. http:// www.who.int/cardiovascular-diseases/guidelines/Fulltext.pdf
42. Goff DCJ, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S49-73
43. NICE. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease: appendices. Published online first. 2014. http://www.nice. org.uk/guidance/cg181/evidence/lipid-modification-updateappendices-243786638
44. NHS Employers. 2015/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF). 2015. http://www. nhsemployers.org/~/media/Employers/Documents/Primary care contracts/QOF/2015-16/2015 16 QOF guidance for stakeholders. pdf
45. Sundstrom J, Arima H, Woodward M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (London, England) 2014;384:591-8
46. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90
47. Grove WM, Zald DH, Lebow BS, et al. Clinical versus mechanical prediction: a meta-analysis. Psychol Assess 2000;12:19-30
48. Lovibond SH, Birrell PC, Langeluddecke P. Changing coronary heart disease risk-factor status: the effects of three behavioral programs. J Behav Med 1986;9:415-37